GENE EXPRESSION BIOMARKERS AND THEIR USE FOR DIAGNOSTIC AND PROGNOSTIC APPLICATION IN PATIENTS POTENTIALLY IN NEED OF HDAC INHIBITOR TREATMENT

摘要

The present invention relates to the utilization of one or more genes selected from the group comprising ZFP64, DPP3, CCDC43, HIST2H4A/B, KDELC2 and MICALL1 as biomarkers for HDAC inhibitor treatment. The expression and/or change of the aforementioned genes are preferably determined via the respective corresponding mRNA or one or more proteins expressed by the aforementioned genes.